Cambridge Healthtech Institute’s Thirteenth Annual

Molecular Diagnostics

Guidelines for Success

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

Molecular diagnostics is poised for significant growth and is driving new markets. Efforts to standardize test development and demonstrate sufficient evidence of clinical utility are critical to the industry so that results can be interpreted reliably and confidently. Yet uncertainty remains around who will be developing guidelines and ensuring proper implementation in healthcare. The demand is growing by consumers, but safeguards need to be put in place and a concerted effort needs to be made to educate the various stakeholders. Join us at the industry leaders networking event to learn guidelines for successful implementation of diagnostics from experts in the field.

Preliminary Agenda

KEYNOTE SESSION: WHY AN ACCURATE DIAGNOSIS IS FUNDAMENTAL TO HEALTH CARE


Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP; AMP 2014 President and Member, AMP Professional Relations Committee

Loren J. Joseph, M.D., Director, Molecular Diagnostics Lab, Pathology, Beth Israel Deaconess Medical Center


CPT ARMAGEDDON TWO YEARS LATER: ARE PATIENT PAY MODELS WORKING?

Brief Introduction: CPT “Story” and Why Some Have Turned to the Patient Pay Model

Daniel H. Farkas, Ph.D., HCLD, FACB, Laboratory Director, Sequenom Center for Molecular Medicine

CPT Armageddon Two Years Later: Are The New Codes Working?

Victoria M. Pratt, Ph.D., FACMG, Director, Pharmacogenomics Laboratory, Medical and Molecular Genetics, Indiana University School of Medicine

Decoding Fertility

Piraye Y. Beim, Ph.D., Founder & CEO, Celmatix Inc.

23andMe: A Decade of Consumer Genomics

Jill Hagenkord, M.D., CMO, 23andMe

Enabling Patient Access to Breast Cancer Genomic Risk Panels

Elad Gil, Ph.D., CEO, Color Genomics

KEYNOTE PRESENTATION: Economic Advantages and Disadvantages of Pharmacogenetics Testing in Large Health Care Systems

David Flockhart, M.D., Ph.D., Chief, Division of Clinical Pharmacology, Indiana University School of Medicine


BREAKTHROUGHS IN PERSONALIZED MEDICINE OUTSIDE ONCOLOGY

15 Years of Personalized Medicine, Can We Move Beyond Oncology?

Eric Lai, Senior Vice President and Head, Pharmacogenomics, Companion Diagnostics, Takeda Development Centers of America

Talk Title to be Announced

Greg Keenan, M.D., Vice President, Medical Affairs & US Head Medical Officer, AstraZeneca


DEVELOPING EVIDENCE TO ESTABLISH CLINICAL VALIDITY OF EMERGING MOLECULAR DIAGNOSTICS

What Clinical Validity Means For Consumers and Clinicians in the New Era of Genomic Medicine

J. Leonard Lichtenfeld, M.D., MACP, Deputy CMO, American Cancer Society, Inc.

SWS COMPETITION
Does your company...
> Stand to improve patient outcomes and healthcare system cost containment?
> Have a value proposition which impresses venture capitalists?

We are currently recruiting privately backed companies to compete in this year’s "Swimming with the Sharks" challenge at the 13th Annual Molecular Diagnostics conference. Selected companies will have the opportunity to pitch their company's clinical value proposition to our expert panel in front of a large targeted audience at this industry flagship event. Click the link below to complete the application form for a chance to compete and have your company reviewed and evaluated.

Top two winners will receive global recognition as the "2016 Tri-Con Most Promising Company", along with detailed feedback including company analysis, feedback and strategy suggestions.

Apply online at http://www.triconference.com/evaluating-start-ups/

Qualifying Criteria:

  • Clinical Utility
  • Investor Readiness
  • Healthcare Impact

Format:

  • 12 companies will give 5 minute presentations in the first round of the competition
  • 5 finalists will be chosen to give a 10 minute presentation in the second round of the competition
  • Summary and Award for top start-ups (first and second place) will be presented by panel of judges

Moderator:

Alan B. Carter, Consultant, Sales Performance International

Panel of Judges:

Harry Glorikian, Healthcare Consultant
Stan Rose, Ph.D., CEO, Transplant Genomics
Mark S. Boguski, M.D., Ph.D., Founder & CMO, Precision Medicine Network, Inc.
Enrico Picozza, MS, Venture Partner, HLM Venture Partners
Paul D. Grossman, Ph.D., Venture Partner, Telegraph Hill Partners
Chris Heid, CFO, Berkeley Angel Network

Selection and Coaching Committee:

Chris Heid, CFO, Berkeley Angel Network
Peter S. Miller, COO, Genomic Healthcare Strategies

TOWARD A PRECISION MEDICINE ECOSYSTEM: Pooling Data to Save Lives

Moderator: J. Marty Tenenbaum, Ph.D., Chairman, Cancer Commons
Panelists:
Marty Tenenbaum, Ph.D., Cancer Commons (panel organizer and moderator)
Lincoln Nadauld, M.D., Intermountain Health
William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, The DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Piers Mahon, Ph.D., Director Global Alliances, Cancer Commons

Premier Sponsors:  

Bina Technologies

Coyote

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large